Source comparison
Comparison Table: MK-677 Downstream Effects vs Direct GH Administration
GH Secretion Pattern Pulsatile. Mimics natural circadian rhythm with peak 90–120 min post-dose Supraphysiological bolus. Immediate spike, no pulsatility MK-677 preserves physiological pulsatility, which may reduce receptor downregulation vs exogenous GH IGF-1
This comparison does not assign a generated winner or score.
- GH Secretion Pattern
- Pulsatile. Mimics natural circadian rhythm with peak 90–120 min post-dose
- Supraphysiological bolus. Immediate spike, no pulsatility
- MK-677 preserves physiological pulsatility, which may reduce receptor downregulation vs exogenous GH
- IGF-1 Elevation
- 39–89% increase sustained across 24 hours at 25mg daily
- 100–300% increase depending on dose, but shorter duration (8–12 hours)
- MK-677 provides steadier IGF-1 elevation; exogenous GH creates higher peaks but requires multiple daily injections for sustained effect
- Cortisol Impact
- 12–18% baseline elevation with chronic use; 22–35% acute spike
- 5–10% baseline elevation; less pronounced acute response
- MK-677's ghrelin agonism drives stronger cortisol response than exogenous GH. Limiting factor in high-stress individuals
- Glucose Metabolism
- Fasting glucose +6–12 mg/dL; HbA1c +0.2–0.4%
- Fasting glucose +8–15 mg/dL; similar HbA1c impact
- Both impair insulin sensitivity, but GH injection allows dose titration and timing flexibility MK-677 lacks
- Appetite Stimulation
- Pronounced (60–75% of users report 20–40% caloric intake increase)
- Minimal to none
- MK-677's ghrelin activity is unique. Exogenous GH does not stimulate appetite, making dietary control easier
- Administration Convenience
- Oral, once daily
- Subcutaneous injection, 1–2× daily for sustained effect
- MK-677 offers practical advantage in research settings where daily injections are logistically difficult